TITLE

Topiramate-induced myoclonus and psychosis during migraine prophylaxis

AUTHOR(S)
Miller, April D.; Prost, Valerie M.; Bookstaver, P. Brandon; Gaines, Kenneth J.
PUB. DATE
July 2010
SOURCE
American Journal of Health-System Pharmacy;7/15/2010, Vol. 67 Issue 14, p1178
SOURCE TYPE
Academic Journal
DOC. TYPE
Case Study
ABSTRACT
Purpose. A case of topiramate-induced myoclonus and acute psychosis in a patient taking the recommended dosage of topiramate for migraine prophylaxis is reported. Summary. A 29-year-old Caucasian, wheelchair-bound woman with diplegic cerebral palsy and a history of migraines was admitted to the hospital after developing paranoid thoughts and episodes of myoclonus two weeks after an increase in her topiramate dosage (25 mg twice daily to 50 mg twice daily). Her physical examination upon admission was unremarkable, with the exception of a temperature of 38.2 °C. Diagnostic laboratory test values, including those of the cerebrospinal fluid, were within normal limits. During neurologic examination, arm jerking, lip smacking, and finger movements occurred spontaneously and unprovoked, and severe bilateral leg myoclonus with plantar stimulation was observed. The results of an ultrasound of her lower extremities and a computed tomography scan of the brain with and without contrast revealed no abnormalities. An electroencephalogram was taken and showed nothing unusual. After nonpharmacologic etiologies were ruled out, her topiramate dosage was decreased and discontinued over four days. Her mental status and myoclonus drastically improved. She was stable and discharged within 24 hours of topiramate discontinuation. Follow-up at six months revealed that her myoclonus had completely resolved. While she has experienced additional psychotic episodes, these were mild and appear to be related to her depression. Myoclonus has not returned. Conclusion. A patient with cerebral palsy experienced myoclonus and acute psychosis after receiving a standard dosage of topiramate for migraine prophylaxis.
ACCESSION #
51870281

 

Related Articles

  • Topiramate in migraine prophylaxis: a randomised double-blind versus placebo study. Mei, D.; Capuano, A.; Vollono, C.; Evangelista, M.; Ferraro, D.; Tonali, P.; Trapani, G. // Neurological Sciences;Dec2004, Vol. 25 Issue 5, p245 

    The objectives of this paper are to evaluate the efficacy and tolerability of topiramate, given at the dose of 100 mg/day, in the prophylactic treatment of migraine. The hypothesis that migraine is the result of a condition of neuronal hyperexcitability and the quest for drugs that are able to...

  • Topiramate.  // Reactions Weekly;1/21/2006, Issue 1085, p26 

    The article presents a case report involving two women who developed anorgasmia during treatment with topiramate for migraine. It relates the irregularities that developed after starting treatment with topiramate. The impact of topiramate on sexual response is discussed.

  • Anticonvulsant reduces migraine headache frequency.  // Formulary;Nov2002, Vol. 37 Issue 11, p569 

    Discusses the findings of a study that the anticonvulsant topiramate reduces migraine frequency. Drug effectiveness; Drug dosage; Mean migraine monthly frequency.

  • Topiramate effective migraine prophylaxis.  // Formulary;Mar2003, Vol. 38 Issue 3, p129 

    Reports on the effectiveness of the antiepileptic, topiramate, in migraine prophylaxis. Recommended dosage; Reduction in the number of migraine episodes; Response rate of patients; Most common adverse effects.

  • Topiramate.  // Reactions Weekly;11/13/2010, Issue 1327, p35 

    The article describes the case of a woman who developed myoclonus and psychosis while receiving treatment with topiramate for migraine.

  • Topiramate.  // Reactions Weekly;6/17/2006, Issue 1106, p18 

    Presents the case of a woman with migraine who developed an obsessive-compulsive disorder during treatment with topiramate. Daily dosage of topiramate received by the patient for one week; Symptoms experienced by the patient after using topiramate.

  • Inconsistent placebo effects in NICE's network analysis. White, Adrian; Cummings, Mike // Acupuncture in Medicine;Dec2012, Vol. 30 Issue 4, p364 

    A letter to the editor is presented on a study conducted by the National Institute for Health and Clinical Excellence (NICE) on the effect of placebo on acupuncture.

  • Topiramate: Is it More Than Prophylaxis of Migraine? From Neurological to Gynecological Indications. Abokrysha, Noha // Turkish Journal of Endocrinology & Metabolism;2009, Vol. 13 Issue 2, p29 

    Topiramate is an anticonvulsant indicated for the treatment of epilepsy and migraine. More recently, it has been used for weight loss with significant success in some populations who have other indications, such as seizure disorders, in addition to obesity, but has not been reported in female...

  • Effects of topiramate use on body composition and resting metabolic rate in migraine patients. Yaman, Mehmet; Ucok, Kagan; Demirbas, Hayri; Genc, Abdurrahman; Oruc, Serdar; Karabacak, Hatice; Koyuncu, Gokhan // Neurological Sciences;Feb2013, Vol. 34 Issue 2, p225 

    Topiramate is an anticonvulsant agent effective in the prophylaxis of migraine, which also induces weight reduction by an unknown mechanism. We investigated the effect of topiramate on resting metabolic rate, anthropometric measurements, and body composition in patients with migraine...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics